Corporate Updates

Novartis Healthcare Launches Sequadra Inhaler for Advance Treatment of COPD Patients

Views: 4.4K
Novartis Healthcare Private Limited launches Sequadra Inhaler, an important advance in treatment of COPD; improves quality of life for COPD patients

Novartis Healthcare Private Limited launches Sequadra Inhaler, an important advance in treatment of COPD; improves quality of life for COPD patients

Novartis Healthcare Private Limited (NHPL) launched Sequadra Inhaler (indacaterol/glycopyrronium) 110mcg/50mcg, a fixed dose combination (FDC) of two bronchodilating active ingredients, indacaterol maleate, a long-acting beta2-adrenergic agonist (LABA) and glycopyrronium bromide, a long-acting anticholinergic (LAMA), for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Sequadra Inhaler is a once-daily dual bronchodilator approved as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. The clinical trials undertaken have shown that it offers statistically significant improvements in bronchodilation compared to treatments widely used as current standards of care, including SFC 50/500 mcg and open-label tiotropium (18 mcg).

India has been part of the global clinical development studies – CQVA149A2303 (n=167), CQVA149A2304 (n=147) and CQVA149A2307 (n=43) of QVA 149. A total of 357 Indian patients were randomised in the aforementioned global studies. Overall, the safety profile and efficacy results in the Indian sub-population were consistent with the global population. At present there are 191 patients from India in the two ongoing studies. Indacaterol/ glycopyrronium combination is currently approved for use in over 76 countries, including countries within the EU, Japan, Canada, countries within Latin America and Australia.

Chronic Obstructive Pulmonary Disease (COPD) is a progressive illness that includes the conditions of emphysema and chronic bronchitis. COPD makes it difficult to breathe, with symptoms that have a destructive impact on patients’ fitness (i.e. activity limitation, decreased mobility) and quality of life. Whilst the symptoms of COPD can be experienced throughout the day, the morning is the most difficult time for patients, who find that their daily routines such as showering and getting ready are significantly slowed down due to COPD symptoms. COPD is often considered to be a disease of later years, but estimates suggest that 50% of those with COPD are below the age of 65, resulting in increases in absenteeism, premature retirement and reductions in workforce participation.

Recommended from all portals

Most Popular

To Top